• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

近视性脉络膜新生血管:当前概念及临床管理的最新进展

Myopic choroidal neovascularisation: current concepts and update on clinical management.

作者信息

Wong Tien Y, Ohno-Matsui Kyoko, Leveziel Nicolas, Holz Frank G, Lai Timothy Y, Yu Hyeong Gon, Lanzetta Paolo, Chen Youxin, Tufail Adnan

机构信息

Singapore Eye Research Institute, Singapore National Eye Centre, National University of Singapore, Singapore, Singapore.

Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan.

出版信息

Br J Ophthalmol. 2015 Mar;99(3):289-96. doi: 10.1136/bjophthalmol-2014-305131. Epub 2014 Jul 1.

DOI:10.1136/bjophthalmol-2014-305131
PMID:24990871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4345796/
Abstract

Choroidal neovascularisation (CNV) is a common vision-threatening complication of myopia and pathological myopia. Despite significant advances in understanding the epidemiology, pathogenesis and natural history of myopic CNV, there is no standard definition of myopic CNV and its relationship to axial length and other myopic degenerative changes. Several treatments are available to ophthalmologists, but with the advent of new therapies there is a need for further consensus and clinical management recommendations. Verteporfin photodynamic therapy has been an established treatment for subfoveal myopic CNV for many years, but this treatment does not restore visual acuity and is associated with long-term chorioretinal atrophy. More recently, clinical trials investigating the efficacy and safety of anti-vascular endothelial growth factor agents in patients with myopic CNV have demonstrated substantial visual acuity gains and quality of life increases compared with photodynamic therapy. These enhanced outcomes provide updated evidence-based clinical management guidelines of myopic CNV, and increase the need for a generally accepted definition for myopic CNV. This review critically summarises the latest myopic CNV literature in the context of clinical experience and recommends a myopic CNV treatment algorithm.

摘要

脉络膜新生血管形成(CNV)是近视和病理性近视常见的威胁视力的并发症。尽管在了解近视性CNV的流行病学、发病机制和自然史方面取得了重大进展,但对于近视性CNV尚无标准定义,也不清楚其与眼轴长度及其他近视性退行性改变的关系。眼科医生有多种治疗方法可供选择,但随着新疗法的出现,需要进一步达成共识并提出临床管理建议。维替泊芬光动力疗法多年来一直是治疗黄斑中心凹下近视性CNV的既定疗法,但这种治疗方法无法恢复视力,且会导致长期脉络膜视网膜萎缩。最近,针对抗血管内皮生长因子药物治疗近视性CNV患者的疗效和安全性的临床试验表明,与光动力疗法相比,患者的视力有显著提高,生活质量也有所改善。这些更好的结果为近视性CNV提供了最新的循证临床管理指南,并增加了对近视性CNV普遍接受定义的需求。本综述结合临床经验对最新的近视性CNV文献进行了批判性总结,并推荐了一种近视性CNV治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/865c/4345796/a5e29c9366a2/bjophthalmol-2014-305131f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/865c/4345796/a5e29c9366a2/bjophthalmol-2014-305131f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/865c/4345796/a5e29c9366a2/bjophthalmol-2014-305131f03.jpg

相似文献

1
Myopic choroidal neovascularisation: current concepts and update on clinical management.近视性脉络膜新生血管:当前概念及临床管理的最新进展
Br J Ophthalmol. 2015 Mar;99(3):289-96. doi: 10.1136/bjophthalmol-2014-305131. Epub 2014 Jul 1.
2
Anti-vascular endothelial growth factor for myopic choroidal neovascularization.抗血管内皮生长因子治疗近视性脉络膜新生血管
Clin Exp Ophthalmol. 2012 Jan-Feb;40(1):e98-e110. doi: 10.1111/j.1442-9071.2011.02684.x.
3
Anti-Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization.抗血管内皮生长因子疗法治疗近视性脉络膜新生血管
Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):554-560. doi: 10.22608/APO.2017308. Epub 2017 Oct 20.
4
Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization.雷珠单抗和光动力疗法治疗近视性脉络膜新生血管后的长期视网膜功能和形态学变化
Retina. 2014 Oct;34(10):2053-62. doi: 10.1097/IAE.0000000000000201.
5
Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.初发性黄斑下近视性脉络膜新生血管经玻璃体腔内注射贝伐单抗治疗后的预后因素。
Am J Ophthalmol. 2013 Dec;156(6):1201-1210.e2. doi: 10.1016/j.ajo.2013.08.002. Epub 2013 Sep 25.
6
Ranibizumab for myopic choroidal neovascularization.雷珠单抗治疗近视性脉络膜新生血管。
Expert Opin Biol Ther. 2020 Dec;20(12):1385-1393. doi: 10.1080/14712598.2021.1830969. Epub 2020 Oct 12.
7
Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.玻璃体腔内注射贝伐单抗或光动力疗法后近视性脉络膜新生血管的视力预后及消退模式比较
Am J Ophthalmol. 2009 Sep;148(3):396-408. doi: 10.1016/j.ajo.2009.03.026. Epub 2009 May 9.
8
Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management.近视性脉络膜新生血管:综述、管理指导和共识声明。
Ophthalmology. 2017 Nov;124(11):1690-1711. doi: 10.1016/j.ophtha.2017.04.028. Epub 2017 Jun 24.
9
Choroidal neovascularization in pathological myopia.病理性近视中的脉络膜新生血管。
Prog Retin Eye Res. 2012 Sep;31(5):495-525. doi: 10.1016/j.preteyeres.2012.04.001. Epub 2012 Apr 28.
10
Choroidal neovascularisation in pathological myopia: an update in management.病理性近视中的脉络膜新生血管:治疗进展
Br J Ophthalmol. 2005 Nov;89(11):1522-8. doi: 10.1136/bjo.2005.074716.

引用本文的文献

1
Efficacy and safety of intravitreal anti-VEGF for myopic choroidal neovascularization.玻璃体内注射抗血管内皮生长因子治疗近视性脉络膜新生血管的疗效与安全性。
Int J Ophthalmol. 2025 Sep 18;18(9):1681-1688. doi: 10.18240/ijo.2025.09.09. eCollection 2025.
2
Double Myopic Choroidal Neovascular Membranes (CNVMs): A Case Report.双眼近视性脉络膜新生血管膜(CNVMs):一例报告
Cureus. 2025 Jun 22;17(6):e86567. doi: 10.7759/cureus.86567. eCollection 2025 Jun.
3
Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review.

本文引用的文献

1
RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.RADIANCE:雷珠单抗治疗病理性近视继发脉络膜新生血管的随机对照研究。
Ophthalmology. 2014 Mar;121(3):682-92.e2. doi: 10.1016/j.ophtha.2013.10.023. Epub 2013 Dec 8.
2
Cardiac issues of noncardiac drugs: the rising story of avastin in age-related macular degeneration.非心脏药物的心脏问题:阿瓦斯汀在年龄相关性黄斑变性中的兴起故事。
Ophthalmologica. 2014;231(2):75-9. doi: 10.1159/000355569. Epub 2013 Nov 2.
3
Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review.
视网膜疾病的临床与社会经济负担:生物类似药能否增添价值?一篇叙述性综述。
Ophthalmol Ther. 2025 Apr;14(4):621-641. doi: 10.1007/s40123-025-01104-3. Epub 2025 Feb 26.
4
Temporal Protrusion of the Optic Disc Implicated in Central Visual Field Abnormalities in High Myopia: Two Case Reports.高度近视中视盘颞侧突出与中心视野异常相关:两例报告
Case Rep Ophthalmol. 2024 Apr 15;15(1):335-342. doi: 10.1159/000538440. eCollection 2024 Jan-Dec.
5
Characterizing Macular Neovascularization in Myopic Macular Degeneration and Age-Related Macular Degeneration Using Swept Source OCTA.使用扫频源光学相干断层扫描血管造影术对近视性黄斑变性和年龄相关性黄斑变性中的黄斑新生血管进行特征分析。
Clin Ophthalmol. 2023 Dec 12;17:3855-3866. doi: 10.2147/OPTH.S440575. eCollection 2023.
6
Recurrence risk of myopic choroidal neovascularisation: a systematic review of current study.近视性脉络膜新生血管的复发风险:当前研究的系统综述。
BMJ Open Ophthalmol. 2023 Oct;8(1). doi: 10.1136/bmjophth-2023-001396.
7
'Structural OCT changes distinguishing between myopic macular haemorrhages due to choroidal neovascularization and spontaneous Bruch's membrane rupture: the "myopic 2 binary reflective sign".区分脉络膜新生血管引起的近视性黄斑出血与自发性玻璃膜破裂的光学相干断层扫描(OCT)结构变化:“近视二元反射征”
Eye (Lond). 2024 Mar;38(4):792-797. doi: 10.1038/s41433-023-02780-w. Epub 2023 Oct 9.
8
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials.抗血管内皮生长因子药物致眼内注射相关性急性肾损伤:系统评价和随机对照试验的荟萃分析。
BioDrugs. 2023 Nov;37(6):843-854. doi: 10.1007/s40259-023-00621-6. Epub 2023 Sep 7.
9
Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised controlled trials.比较抗血管内皮生长因子治疗近视脉络膜新生血管的效果:一项随机对照试验的系统评价和荟萃分析。
BMJ Open. 2023 Jul 20;13(7):e067921. doi: 10.1136/bmjopen-2022-067921.
10
Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment.抗血管内皮生长因子治疗后近视性脉络膜新生血管相关性黄斑萎缩的危险因素。
PLoS One. 2022 Sep 22;17(9):e0273613. doi: 10.1371/journal.pone.0273613. eCollection 2022.
病理性近视及近视性脉络膜新生血管的流行病学和疾病负担:基于证据的系统综述。
Am J Ophthalmol. 2014 Jan;157(1):9-25.e12. doi: 10.1016/j.ajo.2013.08.010. Epub 2013 Oct 5.
4
Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.初发性黄斑下近视性脉络膜新生血管经玻璃体腔内注射贝伐单抗治疗后的预后因素。
Am J Ophthalmol. 2013 Dec;156(6):1201-1210.e2. doi: 10.1016/j.ajo.2013.08.002. Epub 2013 Sep 25.
5
Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.特发性脉络膜新生血管的抗血管内皮生长因子治疗:4 年的结果。
Br J Ophthalmol. 2013 Nov;97(11):1447-50. doi: 10.1136/bjophthalmol-2012-302973. Epub 2013 Sep 11.
6
Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study.雷珠单抗治疗近视性脉络膜新生血管:REPAIR研究的12个月结果
Ophthalmology. 2013 Sep;120(9):1944-5.e1. doi: 10.1016/j.ophtha.2013.06.010.
7
Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia.血管内皮生长因子基因与抗血管内皮生长因子治疗高度近视脉络膜新生血管的反应。
Ophthalmology. 2014 Jan;121(1):225-233. doi: 10.1016/j.ophtha.2013.06.043. Epub 2013 Aug 14.
8
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.抑制年龄相关性脉络膜新生血管中 VEGF 的替代治疗:IVAN 随机对照试验的 2 年发现。
Lancet. 2013 Oct 12;382(9900):1258-67. doi: 10.1016/S0140-6736(13)61501-9. Epub 2013 Jul 19.
9
Intravitreal bevacizumab in myopic neovascular membranes: 24-month results.玻璃体内注射贝伐单抗治疗近视性新生血管膜:24个月的结果。
Ophthalmology. 2013 Jul;120(7):1510-1.e1. doi: 10.1016/j.ophtha.2013.03.006.
10
Evaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes.评估色素上皮衍生因子和补体因子 I 多态性是否为高度近视眼中脉络膜新生血管的原因。
Invest Ophthalmol Vis Sci. 2013 Jun 19;54(6):4208-12. doi: 10.1167/iovs.13-12280.